Pharsight

1. List of Minolira drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103517	EPI HLTH	Pharmaceutical compositions for minocycline	Apr, 2036 (13 years from now)

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 08 May, 2017

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 105MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 135MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription

MINOLIRA family patents

United States

India

2. List of Rhofade drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8815929	EPI HLTH	Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists	Jan, 2024 (10 months from now)
US8420688	EPI HLTH	Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists	Aug, 2024 (1 year, 4 months from now)
US7812049	EPI HLTH	Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists	May, 2028 (5 years from now)
US8883838	EPI HLTH	Pharmaceutical cream compositions and methods of use	Dec, 2031 (8 years from now)
US10335391	EPI HLTH	Stabilized oxymetazoline formulations and their uses	Jun, 2035 (12 years from now)
US10751325	EPI HLTH	Stabilized oxymetazoline formulations and their uses	Jun, 2035 (12 years from now)
US9974773	EPI HLTH	Stabilized oxymetazoline formulations and their uses	Jun, 2035 (12 years from now)
US11517560	EPI HLTH	Stabilized oxymetazoline formulations and their uses	Jun, 2035 (12 years from now)

Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 18 January, 2017

Treatment: Topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream; Once daily topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream, where the patient experiences no rebound or worsening of facial erythema post-treatment; Once daily topical treatment of persistent facial erythema associated with rosacea in adults; Once daily topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream; Once daily topical treatment of persistent facial erythema associated with rosacea in female adults

Dosage: CREAM;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.01	20 Jun, 2019	1	04 Oct, 2021	11 Jun, 2035	Eligible

Strength	Dosage	Availability
1%	CREAM;TOPICAL	Prescription

RHOFADE family patents

United States

Australia

Spain

European Union

Canada

Taiwan, Province of China

Portugal

Hong Kong

Poland

Denmark

Mexico

Japan

3. List of Sitavig drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791127	EPI HLTH	Mucosal bioadhesive slow release carrier for delivering active principles	Mar, 2027 (4 years from now)
US8747896	EPI HLTH	Mucosal bioadhesive slow release carrier for delivering active principles	Jun, 2027 (4 years from now)
US8592434	EPI HLTH	Mucoadhesive buccal tablets for the treatment of orofacial herpes	Jun, 2030 (7 years from now)